Materials based tumor immunotherapy vaccines

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 238-245

  Li, Weiwei Aileen ^a,b   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LIPOSOME; NANOPARTICLE; NSC 87877; POLYGLACTIN; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; BIOENGINEERING; BIOTECHNOLOGY; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELLS; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ORGAN; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

EID: 84877057838     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.12.008     Document Type: Review

References (50)

1. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
2. Huebsch N., Mooney D.J. Inspiration and application in the evolution of biomaterials. Nature 2009, 462:426-432.
3. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3:630-641.
4. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
5. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010, 107:4275-4280.
6. Peggs K.S., Quezada S.A., Korman A.J., Allison J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206-213.
7. Atanackovic D., Altorki N.K., Cao Y., Ritter E., Ferrara C.A., Ritter G., Hoffman E.W., Bokemeyer C., Old L.J., Gnjatic S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008, 105:1650-1655.
8. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., Pavlick A., Escalon J.B., Cruz C.M., Angiulli A., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007, 104:8947-8952.
9. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., Hodi F.S., Liebster L., Lam P., Mentzer S., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998, 95:13141-13146.
10. Simons J.W., Carducci M.A., Mikhak B., Lim M., Biedrzycki B., Borellini F., Clift S.M., Hege K.M., Ando D.G., Piantadosi S., et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006, 12:3394-3401.
11. Longo D.L. New therapies for castration-resistant prostate cancer. N Engl J Med 2010, 363:479-481.
12. Donia M., Hansen M., Sendrup S.L., Iversen T.Z., Ellebaek E., Andersen M.H., Straten P.T., Svane I.M. Methods to improve adoptive T-cell therapy for melanoma: IFN-gamma enhances anticancer responses of cell products for infusion. J Invest Dermatol 2012, [Epub ahead of print].
13. Mackensen A., Meidenbauer N., Vogl S., Laumer M., Berger J., Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006, 24:5060-5069.
14. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105.
15. Kleindienst P., Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003, 170:2817-2823.
16. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
17. Kim J., Mooney D.J. In vivo modulation of dendritic cells by engineered materials: towards new cancer vaccines. Nano Today 2011, 6:466-477.
18. Hori Y., Winans A.M., Huang C.C., Horrigan E.M., Irvine D.J. Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 2008, 29:3671-3682.
19. Ali O.A., Huebsch N., Cao L., Dranoff G., Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009, 8:151-158.
20. Ali O.A., Emerich D., Dranoff G., Mooney D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med 2009, 1:8ra19.
21. Ali O., Doherty E., Bell W., Fradet T., Hudak J., Laliberte M.-T., Mooney D., Emerich D. Biomaterial-based vaccine induces regression of established intracranial glioma in rats. Pharm Res 2011, 28:1074-1080.
22. Swartz M.A., Hirosue S., Hubbell J.A. Engineering approaches to immunotherapy. Sci Transl Med 2012, 4:148rv149.
23. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
24. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
25. Slutter B., Soema P.C., Ding Z., Verheul R., Hennink W., Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release 2010, 143:207-214.
26. Nordly P., Rose F., Christensen D., Nielsen H.M., Andersen P., Agger E.M., Foged C. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J Control Release 2011, 150:307-317.
27. Lee J., Yun K.S., Choi C.S., Shin S.H., Ban H.S., Rhim T., Lee S.K., Lee K.Y. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem 2012, 23:1174-1180.
28. Uto T., Akagi T., Yoshinaga K., Toyama M., Akashi M., Baba M. The induction of innate and adaptive immunity by biodegradable poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 2011, 32:5206-5212.
29. Cho N.-H., Cheong T.-C., Min J.H., Wu J.H., Lee S.J., Kim D., Yang J.-S., Kim S., Kim Y.K., Seong S.-Y. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nano 2011, 6:675-682.
30. Jewell C.M., Bustamante López S.C., Irvine D.J. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci USA 2011, 108:15745-15750.
31. Zhang Z., Tongchusak S., Mizukami Y., Kang Y.J., Ioji T., Touma M., Reinhold B., Keskin D.B., Reinherz E.L., Sasada T. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011, 32:3666-3678.
32. Wang Y., Irvine D.J. Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres. Biomaterials 2011, 32:4903-4913.
33. Slutter B., Jiskoot W. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. J Control Release 2010, 148:117-121.
34. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., Swartz M.A., Hubbell J.A. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci USA 2011, 108:E989-E997.
35. Nochi T., Yuki Y., Takahashi H., Sawada S., Mejima M., Kohda T., Harada N., Kong I.G., Sato A., Kataoka N., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 2010, 9:572-578.
36. Woodrow K.A., Bennett K.M., Lo D.D. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012, 14:17-46.
37. Kwong B., Liu H., Irvine D.J. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials 2011, 32:5134-5147.
38. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012, 33:583-591.
39. Park J., Mattessich T., Jay S.M., Agawu A., Saltzman W.M., Fahmy T.M. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release 2011, 156:109-115.
40. Hu Y., Atukorale P.U., Lu J.J., Moon J.J., Um S.H., Cho E.C., Wang Y., Chen J., Irvine D.J. Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. Biomacromolecules 2009, 10:756-765.
41. Flanary S., Hoffman A.S., Stayton P.S. Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem 2009, 20:241-248.
42. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 2010, 28:7897-7906.
43. Scott E.A., Stano A., Gillard M., Maio-Liu A.C., Swartz M.A., Hubbell J.A. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 2012, 33:6211-6219.
44. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci USA 2012, 109:1080-1085.
45. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., Sohail M., Luo S., Ho Um S., Khant H., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
46. Vasdekis A.E., Scott E.A., O'Neil C.P., Psaltis D., Hubbell J.A. Precision intracellular delivery based on optofluidic polymersome rupture. ACS Nano 2012, 6:7850-7857.
47. Selbo P.K., Weyergang A., Hogset A., Norum O.J., Berstad M.B., Vikdal M., Berg K. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. J Control Release 2010, 148:2-12.
48. Lee J., Sharei A., Sim W.Y., Adamo A., Langer R., Jensen K.F., Bawendi M.G. Nonendocytic delivery of functional engineered nanoparticles into the cytoplasm of live cells using a novel, high-throughput microfluidic device. Nano Lett 2012, 12:6322-6327.
49. Stephan M.T., Stephan S.B., Bak P., Chen J., Irvine D.J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 2012, 33:5776-5787.
50. Stephan M.T., Moon J.J., Um S.H., Bershteyn A., Irvine D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010, 16:1035-1041.